<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02826837</url>
  </required_header>
  <id_info>
    <org_study_id>LEAC-102-01</org_study_id>
    <nct_id>NCT02826837</nct_id>
  </id_info>
  <brief_title>LEAC-102 for Advanced Colorectal Cancer</brief_title>
  <official_title>A Phase I/IIa Dose-Escalation Study Evaluating the Safety, Tolerability and Efficacy of LEAC-102 in Combination With FOLFOX + Bevacizumab/Cetuximab in Subjects With Advanced Colorectal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Taiwan Leader Biotech Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Taiwan Leader Biotech Corp.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Phase I/IIa Dose-Escalation Study Evaluating the Safety, Tolerability and Efficacy of&#xD;
      LEAC-102 in Combination with FOLFOX + Bevacizumab/Cetuximab in Subjects with Advanced&#xD;
      Colorectal Cancer&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 1, 2022</start_date>
  <completion_date type="Anticipated">February 1, 2024</completion_date>
  <primary_completion_date type="Anticipated">February 1, 2024</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum tolerated dose</measure>
    <time_frame>Week 4</time_frame>
    <description>First two cycles of FOLFOX + Bevacizumab/Cetuximab for advanced Colorectal Cancer (cycle length = 2 weeks)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse events (AEs)</measure>
    <time_frame>Weeks 0, 1, 2, 3, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22,24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of serious adverse events (SAEs)</measure>
    <time_frame>Weeks 0, 1, 2, 3, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22,24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response rate</measure>
    <time_frame>Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidences of myelosuppression</measure>
    <time_frame>Weeks Weeks 0, 1, 2, 3, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22,24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in white blood cells (WBCs) level at all post-treatment visits compared to baseline</measure>
    <time_frame>Weeks 0, 1, 2, 3, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22,24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in platelet level at all post-treatment visits compared to baseline</measure>
    <time_frame>Weeks 0, 1, 2, 3, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22,24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in hemoglobin level at all post-treatment visits compared to baseline</measure>
    <time_frame>Weeks 0, 1, 2, 3, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22,24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in serum inflammatory cytokines level at all post-treatment visits compared to baseline</measure>
    <time_frame>Weeks 0, 1, 2, 3, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22,24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in serum c-reactive protein level at all post-treatment visits compared to baseline</measure>
    <time_frame>Weeks 0, 1, 2, 3, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22,24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in global health/QoL standardized score at post-treatment visits compared to baseline</measure>
    <time_frame>Weeks 0, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22,24</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Advanced Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>LEAC-102 and FOLFOX+Bevacizumab/Cetuximab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The subjects will be administered folinic acid (Leucovorin; LV), Fluorouracil (5-FU) and Oxaliplatin (FOLFOX) + Bevacizumab/Cetuximab by intravenous infusion.&#xD;
Cycles repeat every 2 weeks. Dose and schedule modifications may be made at the treating physician's discretion.&#xD;
A standard 3+3 trial design will be used for LEAC-102 dose escalation cohorts.The dosing of LEAC-102 will be divided into 3 cohorts, the subjects will receive LEAC-102 every day&#xD;
Cohort 1: LEAC-102 500 mg capsule, 3 capsules, three times per day for 24 weeks (oral), Cohort 2: LEAC-102 500 mg capsule, 4 capsules, three times per day for 24 weeks (oral), Cohort 3: LEAC-102 500 mg capsule, 5 capsules, three times per day for 24 weeks (oral)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LEAC-102 500mg capsule and FOLFOX + Bevacizumab/Cetuximab</intervention_name>
    <description>The subjects will be administered FOLFOX + Bevacizumab/Cetuximab by intravenous infusion.&#xD;
Cycles repeat every 2 weeks. Dose and schedule modifications may be made at the treating physician's discretion.&#xD;
A standard 3+3 trial design will be used for LEAC-102 dose escalation cohorts.The dosing of LEAC-102 will be divided into 3 cohorts, the subjects will receive LEAC-102 every day&#xD;
Cohort 1: LEAC-102 500 mg capsule, 3 capsules, three times per day for 24 weeks (oral), Cohort 2: LEAC-102 500 mg capsule, 4 capsules, three times per day for 24 weeks (oral), Cohort 3: LEAC-102 500 mg capsule, 5 capsules, three times per day for 24 weeks (oral)</description>
    <arm_group_label>LEAC-102 and FOLFOX+Bevacizumab/Cetuximab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Subjects aged at least 20 years old&#xD;
&#xD;
          2. Histologically or cytologically confirmed measurable and/or evaluable advanced (stage&#xD;
             III/IV) colorectal cancer that can be accurately assessed by CT/MRI scan (RECIST v1.1)&#xD;
             for which regimen of FOLFOX + Bevacizumab/Cetuximab is arranged by the investigator&#xD;
&#xD;
          3. Subjects may be treatment naïve, or may have received therapy for colorectal cancer.&#xD;
&#xD;
          4. ECOG performance status ≤ 2 and life expectancy ≥ 12 months Note: ECOG = Eastern&#xD;
             Cooperative Oncology Group&#xD;
&#xD;
          5. Dated and signed informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Primary CNS malignancies or clinically active CNS metastases Note: CNS = central&#xD;
             nervous system&#xD;
&#xD;
          2. Ascertained hypersensitivity to any component of investigational product or FOLFOX +&#xD;
             Bevacizumab/Cetuximab that the subject will be treated&#xD;
&#xD;
          3. Any of the following hematologic abnormalities:&#xD;
&#xD;
               1. Hemoglobin &lt; 10.0 g/dL,&#xD;
&#xD;
               2. ANC &lt; 1,500/μL,&#xD;
&#xD;
               3. Platelets &lt; 100,000 /μL Note: ANC = absolute neutrophil count&#xD;
&#xD;
          4. Any of the following serum chemistry abnormalities:&#xD;
&#xD;
               1. Total bilirubin &gt; 1.5 × ULN,&#xD;
&#xD;
               2. AST or ALT &gt; 2.5 × ULN,&#xD;
&#xD;
               3. Gamma-GT &gt; 2.5 x ULN,&#xD;
&#xD;
               4. Alk-P &gt; 2.5 x ULN,&#xD;
&#xD;
               5. serum albumin &lt; 3.0 g/dL,&#xD;
&#xD;
               6. creatinine &gt; 1.5 × ULN,&#xD;
&#xD;
               7. any other ≥ Grade 3 laboratory abnormality at baseline (other than those listed&#xD;
                  above)&#xD;
&#xD;
             Note: ULN = upper limit of normal. AST = aspartate transaminase, ALT: alanine&#xD;
             transaminase, Gamma-GT = Gamma-glutamyl transferase, Alk-P = alkaline phosphatase&#xD;
&#xD;
          5. Requirement for ongoing systemic steroid, or immunosuppressive agents&#xD;
&#xD;
          6. Uncontrolled nausea or vomiting or any symptom that would prevent the ability to&#xD;
             comply with daily oral LEAC-102 treatment&#xD;
&#xD;
          7. Active clinically serious infection&#xD;
&#xD;
          8. Known history of HIV or hepatitis B or C Note: HIV = human immunodeficiency virus&#xD;
&#xD;
          9. Uncontrolled psychiatric disorder or altered mental status precluding informed consent&#xD;
             or necessary testing&#xD;
&#xD;
         10. Consumption of herbal preparations/supplements (except for a daily&#xD;
             multivitamin/mineral supplement not containing herbal components) within 2 weeks prior&#xD;
             to the start of Cycle 1 of FOLFOX + Bevacizumab/Cetuximab administration&#xD;
&#xD;
         11. Significant cardiovascular disease, including:&#xD;
&#xD;
               1. Active clinically symptomatic left ventricular failure&#xD;
&#xD;
               2. Active hypertension (diastolic blood pressure &gt; 100 mmHg). Subjects with a&#xD;
                  history of hypertension must have been on stable doses of anti-hypertensive drugs&#xD;
                  for ≥ 4 weeks prior to start of Cycle 1 of FOLFOX + Bevacizumab/Cetuximab&#xD;
                  administration&#xD;
&#xD;
               3. Uncontrolled hypertension: Blood pressure &gt;140/90 mmHg on more than 2&#xD;
                  antihypertensive medications&#xD;
&#xD;
               4. Myocardial infarction, severe angina, or unstable angina within 12 weeks prior to&#xD;
                  start of Cycle 1 of FOLFOX + Bevacizumab/Cetuximab administration&#xD;
&#xD;
               5. History of serious ventricular arrhythmia (i.e., ventricular tachycardia or&#xD;
                  ventricular fibrillation)&#xD;
&#xD;
         12. Significant gastrointestinal disorder(s) that would, in the opinion of the Principal&#xD;
             Investigator, prevent absorption of an orally available agent&#xD;
&#xD;
         13. Has received an investigational agent within 4 weeks of entering this study&#xD;
&#xD;
         14. With any condition judged by the investigator that entering the trial may be&#xD;
             detrimental to the subject&#xD;
&#xD;
        15 Female with childbearing potential who is lactating or has positive urine pregnancy test&#xD;
        at Screening visit&#xD;
&#xD;
        16. Subject with either gender refuses to adopt at least two forms of birth control (at&#xD;
        least one of which must be a barrier method) during the study and until 30 days after study&#xD;
        treatment.&#xD;
&#xD;
        Note: Acceptable forms include:&#xD;
&#xD;
          1. Established use of oral, injected or implanted hormonal methods of contraception.&#xD;
&#xD;
          2. Placement of an intrauterine device (IUD) or intrauterine system (IUS).&#xD;
&#xD;
          3. Barrier methods of contraception: Condom OR Occlusive cap (diaphragm or cervical/vault&#xD;
             caps) with spermicidal foam/gel/film/cream/suppository&#xD;
&#xD;
        17. Subjects with grade 2 or above chronic neuropathy&#xD;
&#xD;
        18. Subjects with known dihydropyrimidine dehydrogenase (DPD) deficiency.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Cora Chen, Ph.D,</last_name>
    <phone>+886-978723555</phone>
    <email>cora_chen@twleaderlife.com</email>
  </overall_contact>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>June 7, 2016</study_first_submitted>
  <study_first_submitted_qc>July 5, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 11, 2016</study_first_posted>
  <last_update_submitted>September 28, 2021</last_update_submitted>
  <last_update_submitted_qc>September 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Advanced Colorectal Cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Cetuximab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

